A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy

Inclusion Criteria: * \>18 y.o. adults able to provide consent * Inoperable or metastatic PSMA-expressing cancer, with significant PSMA expression defined as uptake in at least one lesion that is superior to that of the liver on PSMA positron-emission tomography (PET) within 3 months prior to enrolment * Cancer progression documented within 3 months prior to enrolment as per the investigator's assessment, without initiation of another anti-cancer treatment since (excluding palliative radiation therapy to a minority of the tumor burden), unless that anti-cancer treatment was stopped prematurely because of intolerance * For participants with a cancer other than mCRPC, a recommendation from a multidisciplinary tumor board (MDT) in favor of PSMA RPT must be obtained Exclusion Criteria: * Platelets \< 50 x 106/L * Absolute neutrophil count (ANC) \< 1.0 x 106/L * Eastern Cooperative Oncology Group (ECOG) 4 or prognosis \< 3 months, for cancer-related or other serious medical conditions, as per investigator's assessment * Known presence of central nervous system metastasis at risk of complication, which cannot be adequately stabilized (e.g. radiotherapy or corticoid prophylaxis), as per investigator's assessment * Any condition that would limit the ability to comply with the study protocol, as per investigator's assessment * Pregnancy or breastfeeding (e.g. for female participants with non-prostate cancer)